Cargando…

Safety of azithromycin in paediatrics: a systematic review protocol

INTRODUCTION: Azithromycin is widely used in children not only in the treatment of individual children with infectious diseases, but also as mass drug administration (MDA) within a community to eradicate or control specific tropical diseases. MDA has also been reported to have a beneficial effect on...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Peipei, Zeng, Linan, Xiong, Tao, Choonara, Imti, Qazi, Shamim, Zhang, Lingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598555/
https://www.ncbi.nlm.nih.gov/pubmed/31321320
http://dx.doi.org/10.1136/bmjpo-2019-000469
_version_ 1783430796983402496
author Xu, Peipei
Zeng, Linan
Xiong, Tao
Choonara, Imti
Qazi, Shamim
Zhang, Lingli
author_facet Xu, Peipei
Zeng, Linan
Xiong, Tao
Choonara, Imti
Qazi, Shamim
Zhang, Lingli
author_sort Xu, Peipei
collection PubMed
description INTRODUCTION: Azithromycin is widely used in children not only in the treatment of individual children with infectious diseases, but also as mass drug administration (MDA) within a community to eradicate or control specific tropical diseases. MDA has also been reported to have a beneficial effect on child mortality and morbidity. However, concerns have been raised about the safety of azithromycin, especially in young children. The aim of this review is to systematically identify the safety of azithromycin in children of all ages. METHODS AND ANALYSIS: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, Embase, CINAHL, International Pharmaceutical Abstracts and adverse drug reaction (ADR) monitoring systems will be systematically searched for randomised controlled trials (RCTs), cohort studies, case–control studies, cross-sectional studies, case series and case reports evaluating the safety of azithromycin in children. The Cochrane risk of bias tool, Newcastle-Ottawa and quality assessment tools, and The Joanna Briggs Institute Critical Appraisal tools will be used for quality assessment. Meta-analyses will be conducted to the incidence of ADRs from RCTs if appropriate. Subgroup analyses will be performed in different age and azithromycin dosage groups. ETHICS AND DISSEMINATION: Formal ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication. PROSPERO REGISTRATION NUMBER: CRD42018112629
format Online
Article
Text
id pubmed-6598555
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-65985552019-07-18 Safety of azithromycin in paediatrics: a systematic review protocol Xu, Peipei Zeng, Linan Xiong, Tao Choonara, Imti Qazi, Shamim Zhang, Lingli BMJ Paediatr Open Protocol INTRODUCTION: Azithromycin is widely used in children not only in the treatment of individual children with infectious diseases, but also as mass drug administration (MDA) within a community to eradicate or control specific tropical diseases. MDA has also been reported to have a beneficial effect on child mortality and morbidity. However, concerns have been raised about the safety of azithromycin, especially in young children. The aim of this review is to systematically identify the safety of azithromycin in children of all ages. METHODS AND ANALYSIS: MEDLINE, PubMed, Cochrane Central Register of Controlled Trials, Embase, CINAHL, International Pharmaceutical Abstracts and adverse drug reaction (ADR) monitoring systems will be systematically searched for randomised controlled trials (RCTs), cohort studies, case–control studies, cross-sectional studies, case series and case reports evaluating the safety of azithromycin in children. The Cochrane risk of bias tool, Newcastle-Ottawa and quality assessment tools, and The Joanna Briggs Institute Critical Appraisal tools will be used for quality assessment. Meta-analyses will be conducted to the incidence of ADRs from RCTs if appropriate. Subgroup analyses will be performed in different age and azithromycin dosage groups. ETHICS AND DISSEMINATION: Formal ethical approval is not required as no primary data are collected. This systematic review will be disseminated through a peer-reviewed publication. PROSPERO REGISTRATION NUMBER: CRD42018112629 BMJ Publishing Group 2019-06-19 /pmc/articles/PMC6598555/ /pubmed/31321320 http://dx.doi.org/10.1136/bmjpo-2019-000469 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Protocol
Xu, Peipei
Zeng, Linan
Xiong, Tao
Choonara, Imti
Qazi, Shamim
Zhang, Lingli
Safety of azithromycin in paediatrics: a systematic review protocol
title Safety of azithromycin in paediatrics: a systematic review protocol
title_full Safety of azithromycin in paediatrics: a systematic review protocol
title_fullStr Safety of azithromycin in paediatrics: a systematic review protocol
title_full_unstemmed Safety of azithromycin in paediatrics: a systematic review protocol
title_short Safety of azithromycin in paediatrics: a systematic review protocol
title_sort safety of azithromycin in paediatrics: a systematic review protocol
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6598555/
https://www.ncbi.nlm.nih.gov/pubmed/31321320
http://dx.doi.org/10.1136/bmjpo-2019-000469
work_keys_str_mv AT xupeipei safetyofazithromycininpaediatricsasystematicreviewprotocol
AT zenglinan safetyofazithromycininpaediatricsasystematicreviewprotocol
AT xiongtao safetyofazithromycininpaediatricsasystematicreviewprotocol
AT choonaraimti safetyofazithromycininpaediatricsasystematicreviewprotocol
AT qazishamim safetyofazithromycininpaediatricsasystematicreviewprotocol
AT zhanglingli safetyofazithromycininpaediatricsasystematicreviewprotocol